|
|
|
NCT04165941, NCT05664243
|
U. Alabama, IN8Bio |
Chemotherapy-resistant allogeneic or autologous expanded γδ T cells (DeltEX) |
Glioblastoma |
|
|
|
NCT03533816 |
U. Kansas, IN8Bio |
Allogeneic expanded γδ T cells (EAGD) post-HSCT |
Leukemias and myelodysplastic syndromes |
|
|
|
NCT05886491 |
Takeda |
Allogeneic expanded Vδ1 T cells (TAK012) |
Relapsed /refractory (r/r) AML |
|
|
Unmodified ACT |
NCT05358808 |
TC Biopharm |
Allogeneic expanded γδ T cells (TCB-008) |
r/r AML |
|
|
NCT05015426 |
Lee Moffit Cancer Center |
Allogeneic expanded γδ T cells (AAPC) |
AML |
|
|
NCT05400603 |
Emory University |
Allogeneic expanded γδ T cells |
r/r Neuroblastoma |
|
|
NCT03183206, NCT03183219, NCT03183232, NCT03180437
|
Fuda Cancer Hospital affiliated with Jinan University (Guangzhou) |
Allogeneic expanded Vγ9Vδ2 T cells |
late-stage lung and liver cancer |
|
|
NCT04696705 |
Beijing GD Initiative Cell Therapy Technology |
Allogeneic expanded γδ T cells |
Non-Hodgkin lymphoma, peripheral T cell lymphoma |
|
|
NCT04764513 |
Chinese PLA General Hospital |
Allogeneic expanded γδ T cells |
AML, ALL, myelodysplastic syndromes and lymphoma |
|
|
NCT04765462 |
Chinese PLA General Hospital |
Expanded allogeneic γδ T cells |
Various solid tumours |
|
|
NCT06069570 |
Kiromic BioPharma |
Allogeneic expanded γδ T cells combined with radiotherapy |
Metastatic Non-Small Cell Lung Cancer |
|
|
CAR-ACT |
NCT05546723 |
Luminary |
BAFF-transduced Vδ1+Vδ2 T cells (LMY-920) |
r/r Multiple myeloma |
|
|
NCT04735471, NCT04911478
|
Adicet |
CD20-specific CAR-transduced Vδ1 T cells (ADI-001) |
B cell lymphomas |
|
|
|
NCT05302037 |
Cytomed |
NKG2D ligand-specific CAR-transduced Vγ9Vδ2 T cells (CTM-N2D) |
Solid and hematological tumors |
|
|
|
NCT06193486 |
Lee Moffitt Cancer Center |
PSCA-specific CAR-transduced γδ T cells |
Metastatic Castration Resistant (mcr) Prostate Cancer |
|
|
|
NCT06150885 |
Ever Supreme Biotech |
HLA-G-specific CAR-transduced γδ T cells |
r/r solid tumours |
|
|
Conjugated ACT |
NCT05653271 |
Acepodia |
Anti-CD20 conjugated Vδ2 T cells (ACE1831) |
Non-Hodgkin’s Lymphoma |
|
|
|
NCT06415487 |
Acepodia |
Ant-EGFR conjugated Vδ2 cells (ACE2016) |
Solid tumours |
|
|
γδTCR-ACT |
NCT04688853 |
Gadeta |
aβ T cells transduced with Vγ9Vδ2 TCR (TEG-002) |
r /r multiple myeloma |
|
|
|
NCT04014894 |
Eureka |
CD19-specific antibody/ γδTCR-transduced T cells (ET019003) |
B cell lymphoma |
|
|
|
NCT04864054 |
Eureka |
GPC3-specific antibody/ γδTCR transduced T cells (ECT204) |
Liver cancers |
|
|
|
NCT04502082; NCT04634357
|
Eureka |
Alpha-fetoprotein-specific antibody/ γδTCR transduced T cells (ET140203) |
Liver cancers |
|
|
Engagers |
NCT04243499, NCT05307874
|
ImCheck |
BTN3A agonist (ICT01) |
Hematological and solid tumors |
|
|
|
NCT05369000 |
Lava |
PSMA-targeting bispecific γδ T Cell engager (LAVA-1207) |
mcr Prostate Cancer |
|
|
|
|
|
|
